Guardant Health, Inc. (GH)
158.60
-7.28
(-4.39%)
USD |
NASDAQ |
Oct 16, 16:00
158.63
+0.03
(+0.02%)
After-Hours: 20:00
Guardant Health Research and Development Expense (Annual) : 364.19M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 364.19M |
| December 31, 2024 | 347.75M |
| December 31, 2023 | 365.09M |
| December 31, 2022 | 368.61M |
| December 31, 2021 | 263.22M |
| Date | Value |
|---|---|
| December 31, 2020 | 141.36M |
| December 31, 2019 | 86.29M |
| December 31, 2018 | 50.71M |
| December 31, 2017 | 25.56M |
| December 31, 2016 | 10.86M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Natera, Inc. | 624.11M |
| Quest Diagnostics, Inc. | -- |
| Labcorp Holdings, Inc. | -- |
| OPKO Health, Inc. | 124.03M |
| Psychemedics Corp. | -- |